Please login to the form below

Not currently logged in

S-A invests €350m in vaccine facility

Leading vaccine manufacturer sanofi-aventis is to construct a new manufacturing centre in Neuville-sur-Saône, France

Leading vaccine manufacturer sanofi-aventis is to construct a new manufacturing centre in Neuville-sur-Saône, France.

The new centre, near to Lyon, will come under the remit of the group's vaccine division, Sanofi Pasteur and employ 200 people. The facility will produce 100 million doses of the novel dengue fever vaccine, which is currently under development, and expects to be operational by 2013.

"This new vaccine production centre is the largest investment ever made by sanofi-aventis. It illustrates our commitment to providing solutions to unmet medical needs such as dengue, a disease that potentially puts almost half of the world's population at risk," said Christopher A Viehbacher, CEO of sanofi-aventis.

He went on to say that, including this latest investment, sanofi-aventis has invested over €1bn in vaccine production in France since 2005.

The French company is keen to respond to increasing global health needs through innovation. Earlier this month, sanofi-aventis announced it has invested almost €200m to convert its pharmaceutical production site at Vitry-sur-Seine in France to produce monoclonal antibodies.

13th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....